Editorial: Genetics of pediatric immune-mediated diseases

Editorial on the Research Topic
Genetics of pediatric immune-mediated diseases

Pediatric immune-mediated diseases are a diverse group of conditions in which a child’s immune system mistakenly targets and damages its own tissues, leading to chronic inflammation and other serious health issues. Volume I of our Research Topic, including four diverse studies—from case reports to large-scale genetic analysis—collectively provides a comprehensive, contemporary update on the genetics of pediatric immune-mediated diseases.

Wang et al., in their case report, first described, through a retrospective analysis, a case of X-SCID caused by a novel de novo IL2RG mutation, thereby expanding the known mutation spectrum and highlighting its immunological and diagnostic relevance. The patient’s presentation (chronic diarrhoea, recurrent fever, and anemia, with poor response to antibiotic treatment) and laboratory findings -showing reduced T lymphocytes and NK cells, decreased levels of immunoglobulins (IgG, IgA, IgE) and T. marneffei infection - underline the importance of diagnostic value of integrating phenotypic and molecular analyses in patients with suspected Inborn Errors of Immunity.

In line with this, Li et al. described a case of progressive pseudorheumatoid dysplasia (PPRD) involving a novel cellular communication network factor 6 (CCN6) gene mutation (c. 802T>C and c.624dup) and sacroiliac and hip arthritis, including bone marrow oedema and joint effusion. PPRD is a rare, autosomal recessive arthropathy, often misdiagnosed as juvenile rheumatoid arthritis (JIA), spondyloarthritis (SpA), and other inflammatory diseases clinically. Although it is defined as a noninflammatory disease, the evidence provided by the authors contradicts the previous assumption that PPRD is noninflammatory.

In a larger cohort study Romano et al., the authors genetically characterized 29 pediatric patients with arteriovenous cerebral high-flow shunts. Of the 29 patients, 11 carried variants in genes associated with vascular function, 5 received a genetic diagnosis, 1 child had a variant of uncertain significance in the EPHB4 gene, and 5 reported variants in novel genes probably linked to cerebrovascular disorders. Interestingly, the authors revealed that genotype-phenotype correlations can have significant implications for pathophysiological mechanisms, therapeutic approaches, and outcomes. Accordingly, variants in all known genes associated with arteriovenous cerebral shunts were reported in VGAM patients, whereas cutaneous angiomas were specific to RASA1 mutations.

Lastly, to improve understanding of these diseases, provide insights into early diagnosis and intervention, and support stratified management, Chen et al. analyzed the clinical characteristics and genetic features of children with adverse reactions to the Bacillus Calmette-Guérin (BCG) vaccine. Overall, the study provides a comprehensive clinical and genetic characterization of pediatric adverse reactions to the BCG vaccine over 10 years. By distinguishing between localized BCG-itis and disseminated BCG disease, and further stratifying patients according to underlying primary immunodeficiency, the authors highlight important clinical and immunological markers associated with disease severity and prognosis. The findings underscore the strong association between disseminated BCG disease and severe immune dysfunction, particularly severe combined immunodeficiency, which was linked to markedly higher mortality. Moreover, the authors emphasized the importance of early recognition of warning signs such as fever, hepatosplenomegaly, elevated inflammatory markers, and abnormal immune profiles to facilitate prompt diagnosis and tailored management. Overall, this work contributes valuable evidence supporting early immunological screening and genetic evaluation in infants with BCG vaccine complications, with significant implications for improving outcomes through timely intervention.

Collectively, these contributions emphasize the importance of early immunological screening in infants with clinical complications, as well as the diagnostic value of integrating phenotypic and molecular analyses in patients with suspected Inborn Errors of Immunity.

Author contributions

SM: Writing – original draft, Writing – review and editing. BM: Writing – review and editing.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Acknowledgments

This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH author(s) are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.